Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart-Lung machine at the scene boosts cardiac arrest survival

NCT ID NCT04620070

Disease control Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether starting a portable heart-lung machine (ECPR) right at the scene of a cardiac arrest could save more lives and protect brain function. It included 221 adults aged 18-50 with witnessed cardiac arrest that didn't respond to standard CPR. The goal was to see if on-scene ECPR leads to better survival and less brain damage compared to hospital-based ECPR or no ECPR.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extracorporeal cardiopulmonary resuscitation (ECPR) - a portable heart-lung machine started at the scene
What this could lead to
If successful, this approach could increase survival and reduce brain damage for people who suffer a cardiac arrest outside the hospital.
What could go wrong
This is a completed trial, but results may not apply to all patients. The procedure is complex and carries risks like bleeding or infection. It only helps a specific group of patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

221 people

The number who actually took part.

Started

Oct 2021

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Age between 18 and 50 years, known or as estimated at inclusion by the HEMS physician. * Witnessed arrest (last seen well \<5 min), OR signs of life (gasping, movement) * Initial rhyme is VT/VF OR Suspected of having a pulmonary embolism * Refractory cardiac arrest lasting longer than 20 minutes and shorter than 45 min If age is not exactly known at inclusion and is estimated by the HEMS physician between 18 and 50 years but finally the patient appears to be younger or older, the patient will not be excluded. Exclusion Criteria: * \- CO2 et\<1.2 kPa (10 mmHg) during CPR * No clear echographic visualisation of either the femoral artery or the femoral vein. * Expected time from collapse to arrival at an ECPR center with a direct available ECPR team is less than 30 min. The following patients will be withdrawn after initial inclusion as soon as the following information becomes available: * Known malignancy * Known intracranial haemorrhage/ischemia \<6 weeks * Care dependent for daily activities before arrest * Patients with a "do not resuscitate" order, which was not known at time of the arrest. * Refusal of deferred consent by the next of kin or by the patient himself to use the data. Deferred consent will not be asked to relatives of patients who die in scene, but are included in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac arrest are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiac arrest Out-of-Hospital Cardiac Arrest

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac arrest Extracorporeal membrane oxygenation

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, Netherlands

  • ErasmusMC

    Rotterdam, 3015GD, Netherlands

  • Radboud

    Nijmegen, Netherlands

  • UMCG

    Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.